75F40121Q00115 - Synoptics Group G:BOX Chemi XX9 Imaging System (Brand Name or Equal)

This is a combined synopsis/solicitation for commercial services prepared in accordance with the format in FAR 12.6 as supplemented with FAR 13 and additional information included in this notice. The incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2021-06.

THIS ANNOUNCEMENT CONSTITUTES THE ONLY SOLICITATION. A SEPARATE SOLICITATION DOCUMENT (I.E. STANDARD FORM) WILL NOT BE ISSUED.

The solicitation number for this acquisition is RFQ-FDA-75F40121Q00115 and is being issued as a Request for Quote (RFQ). The NAICS Code for this solicitation: 334516 Analytical Laboratory Instrument Manufacturing. The Small Business Size Standard is 1,000 employees.

This is a Brand Name or Equal 100% Small Business Set-Aside RFQ. Simplified acquisition procedures will be utilized.

The U. S Food & Drug Administration (FDA), Office of Acquisitions and Grant Services (OAGS) requires one (1) Synoptics Group G:BOX Chemi XX9 Imaging System or equal.  

Inquires

Offerors must submit all questions concerning this solicitation in writing electronically to adam.powell@fda.hhs.gov. Questions must be received no later than August 3, 2021. Any responses to questions will be made in writing, without identification of the questioner, and will be included in an amendment to the solicitation. Even if provided in other form, only the question responses included in the amendment to the solicitation will govern performance of the contract. 

BACKGROUND INFORMATION

The Laboratory of Respiratory & Pediatric Virus requires an updated gel imaging system to efficiently analyze DNA gels, protein gels, and protein immunoblots in the laboratory. Our current system is not capable of fluorescent detection, which is better suited for sensitivity and quantitation purposes. Since multiple detection methods are used, an imaging system with multiple applications is essential. A gel imaging system will assist in the identification of linear and conformational epitopes recognized by human antibodies and will facilitate the evaluation of the protective immune response to RSV.

The gel imaging system will be used in multiple ways in the laboratory. A system with colorimetric, chemiluminescence and fluorescence detection is needed. The immediate use is to analyze PCR products, molecular clones, protein gels & immunoblots. The laboratory has previously identified distinct regions within the RSV fusion protein (RSV-F) that are involved in virus binding and infectivity. The laboratory will now evaluate the human immune response to these different regions utilizing laboratory techniques that require imaging analysis. Fluorescence detection allows the capability to multiplex (i.e. look at two different proteins at the same molecular weight using different fluorophores). This capability is not possible with chemiluminescence.

Note: Reference attachment titled, "FDA-RFQ-75F40121Q00115," for complete combined synopsis solicitation.